Abstract
P78: Secukinumab treatment results in sustained improvement in absolute Psoriasis Area and Severity Index and Dermatological Life Quality Index in biologic‐naïve and biologic‐experienced patients with moderate‐to‐severe plaque psoriasis: analysis of 12 months of follow‐up data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
